Phase 2Completed
Safety and Efficacy of S-707106 in Subjects With Type 2 Diabetes Mellitus and Inadequate Glycemic Control With Metformin Therapy
A Phase 2, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study of S-707106 in Subjects With Type 2 Diabetes Mellitus and Inadequate Glycemic Control With Metformin Therapy
- Sponsor
- Shionogi (Industry)
- Enrolment
- 218 enrolled
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- S-707106 Dose A; S-707106 Dose B; S-707106 Dose C; Placebo A tablet; Metformin
- Ages
- adults, older adults
- Registry
- NCT01240759
Full record on ClinicalTrials.gov
From the registry
The purpose of this study is to evaluate the safety and efficacy of S-707106 co-administered with metformin in subjects with type 2 diabetes mellitus.
Primary outcomes
- Change from Baseline to Week 12 in Hemoglobin A1c (HbA1c)
History
Last registry update
Study completion
Primary completion
Registered
Started